6-甲氧基-3-甲基苯并呋喃-2-甲酸 | 10410-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 6-甲氧基-3-甲基苯并呋喃-2-甲酸
• 中文别名: 6-甲氧基-3-甲基-1-苯并呋喃-2-羧酸；6-甲氧基-3-甲基-苯并呋喃-2-羧酸
• 英文名称: 6-methoxy-3-methylcoumarilic acid
• 英文别名: 3-methyl 6-methoxybenzofuran-2-carboxylic acid；6-Methoxy-3-methyl-1-benzofuran-2-carboxylic acid
• CAS: 10410-29-4
• 化学式: C₁₁H₁₀O₄
• 分子量: 206.198
• InChiKey: CQZZSFNTQLCLJF-UHFFFAOYSA-N

物化性质

• 熔点：
  187 °C
• 沸点：
  367.1±37.0 °C(Predicted)
• 密度：
  1.295±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-甲氧基-3-甲基苯并呋喃-2-甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 6-methoxy-3-methyl-benzofuran-2-carbonyl chloride
  参考文献：
  名称：

  钯催化的对映选择性分子内脱芳基反应

  摘要：

  对映选择性分子内脱芳基 Heck 反应是通过 Pd 催化的芳基卤化物或芳基三氟甲磺酸酯与吲哚、苯并呋喃、吡咯和呋喃的内部 C=C 键的交叉偶联开发的。各种结构独特的螺杂环和具有 N/O 取代的季碳立体中心和环外烯烃部分的苯并杂环以中等至优异的产率提供，具有良好至优异的对映选择性，显示了本协议的广泛范围。合成了一系列新的基于 BINOL 和 H8-BINOL 的亚磷酰胺配体，并证明在 C2 系底物形成螺杂环的反应中是有效的手性配体。(S)-SEGPHOS 被证明是用于传递苯并稠合二氢吲哚和吡咯啉的反应的良好配体。

  DOI：

  10.1021/jacs.8b09186
• 作为产物：
  描述：

  2,4-二羟基苯乙酮 在 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 6-甲氧基-3-甲基苯并呋喃-2-甲酸
  参考文献：
  名称：

  Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design

  摘要：

  A novel series of 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives featured with various C-2 substituents were designed and synthesized as Mnks inhibitors through fragment-based drug design. Among them, 5b, 51, 5o and 8k showed the best Mnk2 inhibitory activity with IC 50 values of 1.45, 1.16, 3.55 and 0.27 mu M, respectively. And these compounds inhibited the activity of Mnkl at the same time. Furthermore, compounds 50 and 8k exhibited anti-proliferative effects to human leukemia cancer THP-1 and MOLM-13 cell lines and colon cancer HCT-116 cell line. Moreover, Western blot assay suggested that 8k could decrease the levels of p-eIF4E in a dose-dependent manner in HCT-116 cells. Docking studies demonstrated strong interactions between 8k and Mnk2. Therefore, this unique benzofuran scaffold demonstrated great potential to be further explored as potent Mnks inhibitors with improved potency. (C) 2018 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2018.05.004

文献信息

• Synthesis, pharmacological studies and molecular modeling of some tetracyclic 1,3-diazepinium chlorides
  作者：Julie-Ann A. Grant、Tamicka Bonnick、Maxine Gossell-Williams、Terry Clayton、James M. Cook、Yvette A. Jackson

  DOI：10.1016/j.bmc.2009.11.032

  日期：2010.1

  Seven new 1,3-diazepinium chlorides exhibiting some structural similarities to the 1,4-benzodiazepines were synthesized. In a Hippocratic screen using mice, three of these salts, 3-methoxy-6-oxo-7,13-dihydro-6H-benzofuro[2,3-e]pyrido[1,2-a][1,3]diazepin-12-ium chloride (8a), 3-methoxy-9-methyl-6-oxo-7,13-dihydro-6H-benzofuro[2,3-e]pyrido[1,2-a][1,3]diazepin-12-ium chloride (8c) and 3-methoxy-11-methyl-6-oxo-7

  合成了七个与1,4-苯并二氮杂exhibit具有某些结构相似性的新的1,3-二氮杂pin鎓氯化物。在使用小鼠的希波克拉底筛选中，这些盐中的三种为3-甲氧基-6-氧代-7,13-二氢-6 H-苯并呋喃[2,3- e ]吡啶基[1,2- a ] [1,3] diazepin-12-氯化铵（8a），3-甲氧基-9-甲基-6-氧代-7,13-二氢-6 H-苯并呋喃[2,3- e ]吡啶[1,2- a ] [1， 3] diazepin-12-氯化铵（8c）和3-甲氧基-11-甲基-6-氧代-7,13-二氢-6 H-苯并呋喃[2,3- e ]吡啶[1,2- a ] [ 1,3] diazepin-12-chlorium（8e）检查了它们对中枢神经系统的影响，并比较了地西epa的活性。盐8a，8c和8e本身对动物的行为没有镇静作用。然而，他们与地西epa联合使用对地西epa诱导的活动具有显著作用，例如
• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US20030144175A1

  公开（公告）日：2003-07-31

  The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了4-氨基-氮杂七环-3-酮蛋白酶抑制剂及其药用可接受的盐、水合物和溶剂化物，其抑制蛋白酶，包括卡特普辛K，这些化合物的药物组合物，这些化合物的新中间体，以及治疗骨骼过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说，是骨关节炎和类风湿关节炎；帕吉特病；恶性高钙血症；和代谢性骨病，包括通过向需要的患者施用本发明化合物来抑制骨质流失或过度软骨或基质降解。
• NOVEL COMPOUNDS
  申请人：HEIMANN Annekatrin

  公开号：US20130158042A1

  公开（公告）日：2013-06-20

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R 1 , R 2 , R 3 , R 4 , Q have meanings given in the description.

  这项发明涉及公式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。R1，R2，R3，R4，Q在描述中给出了含义。
• Expedited synthesis of benzofuran-2-carboxylic acids via microwave-assisted Perkin rearrangement reaction
  作者：Karla-Sue C. Marriott、Rena Bartee、Andrew Z. Morrison、Leonard Stewart、Julian Wesby

  DOI：10.1016/j.tetlet.2012.04.075

  日期：2012.6

  3-Halocoumarins are readily converted into benzofuran-2-carboxylic acids via a Perkin (coumarin–benzofuran ring contraction) rearrangement reaction. This rearrangement entails initial base catalyzed ring fission. The resulting phenoxide anion then attacks a vinyl halide to produce the final benzofuran moiety. We explored this reaction under microwave reaction conditions and were able to significantly

  3-卤香豆素很容易通过 Perkin（香豆素-苯并呋喃环收缩）重排反应转化为苯并呋喃-2-羧酸。这种重排需要初始碱催化环裂变。所得酚盐阴离子然后攻击乙烯基卤化物以产生最终的苯并呋喃部分。我们在微波反应条件下探索了该反应，能够显着减少反应时间并获得一系列苯并呋喃-2-羧酸衍生物的高产率。
• BENZOFURAN COMPOUNDS, COMPOSITIONS, KITS AND/OR METHODS THEREOF
  申请人：Savannah State University

  公开号：US20150133498A1

  公开（公告）日：2015-05-14

  Benzofuran compound, composition thereof, kit thereof, and/or method thereof. A benzofuran-2-carboxamide moiety may be N-arylated and/or N-alkylated, and the resulting benzofuran compound may be a sigma receptor ligand that binds to, e.g., a σ1 receptor and/or a σ2 receptor with relatively high affinity and/or selectivity. For example, the benzofuran compound may be 5,6-dimethoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide, 3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide, or 6-methoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide. The composition may include the benzofuran compound and a pharmaceutically acceptable carrier.

  苯并呋喃化合物、其组成物、套件以及/或方法。苯并呋喃-2-羧酰胺基团可以被N-芳基化和/或N-烷基化，从而产生的苯并呋喃化合物可以是与σ1受体和/或σ2受体具有相对高亲和力和/或选择性的σ受体配体。例如，苯并呋喃化合物可以是5,6-二甲氧基-3-甲基-N-苯基-N-(3-哌啶基)丙基)苯并呋喃-2-羧酰胺、3-甲基-N-苯基-N-(3-哌啶基)丙基)苯并呋喃-2-羧酰胺或6-甲氧基-3-甲基-N-苯基-N-(3-哌啶基)丙基)苯并呋喃-2-羧酰胺。该组成物可以包括苯并呋喃化合物和药学上可接受的载体。

表征谱图